Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 1/20 | 0.45 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582386 | 0.86 | TSHR (0.55) | KDM4EKMT2AMAPK1L3MBTL1CYP1A2 | |
| SCHEMBL30288437 | 0.86 | KDM4E (0.51) | KDM4EKMT2AMAPK1L3MBTL1CYP1A2 | |
| SCHEMBL8630313 | 0.86 | KDM4E (0.51) | KDM4EKMT2AMAPK1L3MBTL1CYP1A2 | |
| SCHEMBL1506709 | 0.85 | KDM4E (0.49) | KDM4EKMT2AMAPK1L3MBTL1CYP1A2 | |
| SCHEMBL5162666 | 0.85 | KDM4E (0.49) | KDM4EKMT2AMAPK1L3MBTL1CYP1A2 | |
| SCHEMBL1506611 | 0.85 | ALDH1A1 (0.50) | KDM4EKMT2AMAPK1L3MBTL1CYP1A2 | |
| SCHEMBL11090058 | 0.84 | KDM4E (0.49) | KDM4EKMT2AMAPK1L3MBTL1TSHR | |
| SCHEMBL8905796 | 0.84 | TDP1 (0.47) | KDM4EKMT2AMAPK1L3MBTL1TSHR | |
| SCHEMBL3098451 | 0.84 | TSHR (0.49) | KDM4EKMT2AMAPK1L3MBTL1CYP1A2 | |
| SCHEMBL28244436 | 0.83 | KDM4E (0.48) | KDM4EKMT2AMAPK1L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4459409-A | METHYL-QUINOLINECARBOXYLIC ACID, OXIDATION, NICKEL PEROXIDE | AMERICAN CYANAMID COMPANY (US) | 1984-07-10 | — | — | US | claimed |
| EP-2539342-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8969376-B2 | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-03 | — | — | US | disclosed |
| EP-2539342-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| WO-2011105628-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE3B, PDE3A, PDE5A | KDM4E 408/4885KMT2A 1357/4885MAPK1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.